NCT03764917Unknown不适用
Study on the Effect of NGS Combined With RNAseq on Tumor Immune Escape in Advanced Non-small Cell Lung Cancer EGFR and ALK Mutant Negative Patients
Shanghai Pulmonary Hospital, Shanghai, China1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2018年12月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- numbers of immune cells
研究概览
简要总结
Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq
详细描述
Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq. Detecting non-small cell lung cancer patient NGS and RNAseq data before first-line chemotherapy, after two cycles chemotherapy and after disease progression.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Non-small cell lung cancer patient First-line chemotherapy with platinum-based chemotherapy
排除标准
- •EGFR mutant positive Alk mutant positive
结局指标
主要结局
numbers of immune cells
时间窗: 24 months
detecting numbers of immune cells before first-line chemotherapy, after two cycles chemotherapy and after disease progression
次要结局
- numbers of tumor mutations(24 months)
研究者
Caicun Zhou
Prof. Caicun Zhou
Shanghai Pulmonary Hospital, Shanghai, China
研究点 (1)
Loading locations...
相似试验
已完成
不适用
K-RAS and EGFR in Lung CancerNon Small Cell Lung CancerNCT03951233Hellenic Cooperative Oncology Group424
终止
不适用
A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy TreatmentNon-Squamous Non-Small Cell Lung CancerNCT01990261Hoffmann-La Roche33
进行中（未招募）
1 期
Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Metastatic Non Small Cell Lung CancerNCT04743505Washington University School of Medicine27
已完成
1 期
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung CancerNCT02157883AstraZeneca39
尚未招募
不适用
The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC PatientsNSCLCNCT06496009Shanghai Pulmonary Hospital, Shanghai, China845